FERUMOXTRAN-10
drugOn this page
Also known as AMI-227BMS 180549BMS-180549CODE 7227CODE-7227E 172 REDFerric oxideFerric oxide (anhydrous)Ferumoxtran 10RED IRON OXIDE R 1599D
Summary
Ferumoxtran-10 (CHEMBL2108514) is a phase-3 clinical-stage unknown.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Clinical trials: 5
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108514 |
| Name | FERUMOXTRAN-10 |
| Type | Unknown |
| Max phase | 3 |
Also known as: AMI-227, BMS 180549, BMS-180549, CODE 7227, CODE-7227, E 172 RED, Ferric oxide, Ferric oxide (anhydrous), Ferumoxtran 10, Ferumoxtran-10, RED IRON OXIDE R 1599D, FERUMOXTRAN-10
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
0 indications (0 at ChEMBL trial phase 4).
Clinical trials
Total trials: 5.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 2 |
| PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02751606 | PHASE3 | UNKNOWN | Nano MRI on 7 Tesla in Rectal and Breast Cancer |
| NCT00107484 | PHASE2 | COMPLETED | Magnetic Resonance Imaging Using Ferumoxtran-10 in Finding Metastases to the Axillary Lymph Nodes in Patients With Breast Cancer |
| NCT00416455 | PHASE1/PHASE2 | COMPLETED | Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer |
| NCT00659334 | PHASE2 | TERMINATED | Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation |
| NCT00147238 | Not specified | TERMINATED | A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.